EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)ÄquivalenzstudieOpen Access · CC BY 4.0

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age

Murdo Ferguson, Tino F Schwarz, Sebastián A Núñez, Juan Rodríguez-García, Marek Mital, Carlos Zala, Bernhard Schmitt, Nicole Toursarkissian, Dolores Ochoa Mazarro, Josef Großkopf, Christine Voors-Pette, Hemalini Mehta und 10 weitere

Clinical Infectious Diseases · 05.08.2024

DOI: 10.1093/cid/ciae364 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.08.2024. Verfasst von Murdo Ferguson und 21 weiteren Autor:innen. Beteiligte Einrichtung: Colchester Research Group, Truro, Canada. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Antibodies, Viral, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals, BHP HRSA HHS, SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVPreF3 OA) is approved in adults aged ≥60 years. We evaluated RSVPreF3 OA immunogenicity and safety in adults aged 50–59 years without or with increased risk for RSV disease due to specific chronic medical conditions.

Methods

This observer-blind, phase 3, noninferiority trial included adults aged 50–59 years, stratified into 2 subcohorts: those with and those without predefined, stable, chronic medical conditions leading to an increased risk for RSV disease. Participants in both subcohorts were randomized 2:1 to receive RSVPreF3 OA or placebo. A control group of adults aged ≥60 years received RSVPreF3 OA. Primary outcomes were RSV-A and RSV-B neutralization titers (geometric mean titer ratios and sero-response rate differences) 1 month post-vaccination in 50–59-year-olds versus ≥60-year-olds. Cell-mediated immunity and safety were also assessed.

Results

The exposed population included 1152 participants aged 50–59 years and 381 participants aged ≥60 years. RSVPreF3 OA was immunologically noninferior in 50–59-year-olds versus ≥60-year-olds; noninferiority criteria were met for RSV-A and RSV-B neutralization titers in those with and those without increased risk for RSV disease. Frequencies of RSVPreF3-specific polyfunctional CD4+ T cells increased substantially from pre- to 1 month post-vaccination. Most solicited adverse events had mild-to-moderate intensity and were transient. Unsolicited and serious adverse event rates were similar in all groups.

Conclusions

RSVPreF3 OA was immunologically noninferior in 50–59-year-olds compared to ≥60-year-olds, in whom efficacy was previously demonstrated. The safety profile in 50–59-year-olds was consistent with that in ≥60-year-olds. Clinical Trial Registration ClinicalTrials.gov: NCT05590403.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus InfectionsAntibodies, ViralRespiratory Syncytial Virus, HumanHumansMiddle AgedMaleFemaleAgedAntibodies, NeutralizingImmunogenicity, VaccineViral Fusion ProteinsAge FactorsVaccinationImmunity, Cellular

Stichwörter der Autor:innen

chronic conditionshumoral immunityrespiratory syncytial virussafetyvaccination

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, NeutralizingViral Fusion ProteinsF protein, human respiratory syncytial virus

Autor:innen und Institutionen

  • Colchester Research Group, Truro, Canada.
  • Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg Mitte, Würzburg, Germany.
  • Infectología, Centro Medico Maffei, Buenos Aires, Argentina.
  • Preventive Medicine Department, Immunocompromised Patient Immunization Unit, Son Espases University Hospital, Palma de Mallorca, Mallorca, Balearic Islands, Spain.
  • Agnieszka Mital Centrum Badan Clinic, Elblag, Poland.
  • Vacunar, Sede Las Cañitas, Buenos Aires, Argentina.

ORCID-Profile: Corinne Vandermeulen

Förderung

  • GlaxoSmithKline Biologicals
  • BHP HRSA HHS
  • SA

Zitieren

APA

Ferguson, M., Schwarz, T. F., Núñez, S. A., Rodríguez-García, J., Mital, M., Zala, C., Schmitt, B., Toursarkissian, N., Mazarro, D. O., Großkopf, J., Voors-Pette, C., Mehta, H., Hailemariam, H. A., de Heusch, M., Salaun, B., Damaso, S., David, M. P., Descamps, D., Hill, J., …, & RSV OA=ADJ-018 Study Group (2024). Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae364

Vancouver

Ferguson M, Schwarz TF, Núñez SA, Rodríguez-García J, Mital M, Zala C, et al. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae364

BibTeX
@article{Ferguson2024,
  author = {Ferguson, Murdo and Schwarz, Tino F and Núñez, Sebastián A and Rodríguez-García, Juan and Mital, Marek and Zala, Carlos and Schmitt, Bernhard and Toursarkissian, Nicole and Mazarro, Dolores Ochoa and Großkopf, Josef and Voors-Pette, Christine and Mehta, Hemalini and Hailemariam, Hiwot Amare and de Heusch, Magali and Salaun, Bruno and Damaso, Silvia and David, Marie-Pierre and Descamps, Dominique and Hill, Judith and Vandermeulen, Corinne and Hulstrøm, Veronica and RSV OA=ADJ-018 Study Group, RSV OA=ADJ-018 Study Group},
  title = {Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae364}
}
Kostenlos starten →